Navigation Links
Signature Biologics Announces Entry Into the Perinatal Allograft Tissue Market With Commercially Available Flowable Umbilical Cord and Amniotic Allograft Tissue Products
Date:2/2/2019

Signature Matrix and Signature Cord are the culmination of decades of research and clinical use of perinatal tissue by applied stem cell research expert and Amazon best-selling author, Neil Riordan, PA, PhD, and his experienced research and development team. Signature Cord is a flowable umbilical cord tissue allograft that originates from the same tissue used to manufacture the purified, expanded mesenchymal stem cell product used by Stem Cell Institute in Panama to treat a variety of chronic conditions. This product is a natural source of growth factors and hyaluronic acid, and is naturally immune evasive. Most importantly, our proprietary Signature Process of manufacturing does not alter the innate regenerative properties of the umbilical cord tissue and maintains the source material integrity required for tissue repair.

Signature Matrix is a flowable allograft derived from the amniotic membrane,which serves to protect and cushion the embryo during pregnancy. The Signature Process for Signature Matrix production utilizes sophisticated, standardized processing techniques that preserve the amniotic tissue integrity and growth factors to ensure the maximum potential for enhancing the body’s natural healing ability.

In addition to the rollout of these exciting new product lines, Signature Biologics has implemented a state-of-the-art imaging and microscopy system to fully showcase the characteristics and biological profiles of each product and to demonstrate that which sets them apart from other products currently on the market.

We cordially invite all providers to apply for the opportunity to tour our production facility and Riordan Medical Institute in the Dallas-Forth Worth metroplex. Interested providers will also have the opportunity to garner information on the process of becoming a Riordan Medical Institute affiliate provider.

To learn more about our products or to apply to tour the Signature Biologics production facility and Riordan Medical Institute please visit: signaturebiologics.com/provider-application/

About Signature Biologics
Our Mission: Signature Biologics aspires to use its innovative techniques to manufacture human placental derived products to significantly improve and support the natural healing process of the body. We strive to provide best-in-class products that improve the quality of life of patients.

Our Vision: To become the premier, trusted source of innovative placental-derived therapeutic solutions in the nation, characterized by the highest quality and improved functional patient outcomes.

Read Dr. Riordan’s Amazon #1 Best Seller: Stem Cell Therapy: A Rising Tide – How Stem
Cells Are Disrupting Medicine and Transforming Lives
Learn more about Riordan Technologies: neilriordan.com/about

Read the full story at https://www.prweb.com/releases/signature_biologics_announces_entry_into_the_perinatal_allograft_tissue_market_with_commercially_available_flowable_umbilical_cord_and_amniotic_allograft_tissue_products/prweb16072354.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. AMIA Announces 2018 Signature Award and Leadership Award Recipients
2. First Ever Delos Wellness Signature™ Residence in Hawaii on the Market
3. One Million Solutions in Health™ Announces a Signature Square™ Event for a Unique Tumor-Associated Antigen for Cancer Vaccine
4. One Million Solutions in Health™ Announces a First Milestone in Signature Square™ Program to Accelerate the Movement of New Technology from the Scientist to the Patient
5. One Million Solutions in Health’s Technology Evaluation Consortium™ Evaluated GelCel as NOVEL in its Signature Square™ Program
6. Custom Cambridge Mesh is a Signature Architectural Feature of New Georgia BioScience Training Center
7. Shimadzu's Energy Dispersive X-Ray Fluorescence Spectrometers Now Compliant With US FDA Electronic Signature Regulation
8. Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool
9. GenomeDxs Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting
10. TPS Designs New Industrial Oven with Multi-Lane Conveyor System and Secure Thermal Process that Meets FDA Title 21 Part 11 C.F.R For Electronic Signatures
11. Signature Healthcare and the Fertility Centers of New England Announce Clinical Affiliation Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... Join Forrest ... Southeast Region of Sequence, Inc. for an informative session on ... Design Flexibility: Key elements to incorporate into facility design to add manufacturing flexibility ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... the life sciences industry, today announced the opening of a new office in ... Red Nucleus R&D. , Red Nucleus announced the new office in response to ...
(Date:2/10/2020)... ... 2020 , ... R3 Medical Training announced it is now registering for its ... The course is hands on involving real patients and stem cell biologics, with every ... Stem Cell Training Course has received rave reviews from attendees, who love the hands ...
(Date:2/3/2020)... ... February 03, 2020 , ... Global ... announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is ... product featuring locus-multiplexing and short library preparation, for HLA genotyping from sample to ...
Breaking Biology Technology:
(Date:2/13/2020)... ... 13, 2020 , ... Pharmica Consulting announced it will attend ... focusing on all facets of clinical trial planning and management. Pharmica will be ... , “We have attended the SCOPE Summit every year and are excited ...
(Date:2/11/2020)... ... February 11, 2020 , ... Modality ... it achieved its ISO 9001:2015 registration by certification body Intertek. Modality Solutions’ Quality ... reviewed and revised all existing Standard Operating Procedures (SOPs) and created ten new ...
(Date:2/11/2020)... , ... February 11, 2020 , ... ... into The LaunchPort™ medical device accelerator in Port Covington, Baltimore. The newly formed ... that must be addressed to manage increased demand for home dialysis treatments. The ...
Breaking Biology News(10 mins):